No Detail Found!

Interstitial Lung Disease in Dermatomyositis and Polymyositis in Patients from Saudi Arabia: A Single Tertiary Centre Retrospective Study

Author(s)
Hussam A. Alsulmi Department of Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia; 1Department of Medicine, Medical City, Qassim University, Qassim, Saudi Arabia
Rayan Alfadda Department of Rheumatology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Omar Altasan Department of Rheumatology, Alrass General Hospital, Alrass, Al-Qassim, Saudi Arabia
Moath AlHarbi Department of Rheumatology, Buraydah Central Hospital, Qassim Health Cluster, Qassim
Mousa N. Alrashdi Department of Rheumatology, King Fahad Specialist Hospital, Qassim Health Cluster, Qassim, Saudi Arabia
Hatun S. AlHenaki Department of Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia
Abstract
Background: Interstitial lung disease (ILD) is a major extra-muscular manifestation of dermatomyositis (DM) and polymyositis (PM), yet data from Middle Eastern populations remain sparse. We aimed to characterize radiologic ILD patterns, severity, clinical-serologic correlates, and treatment usage among Saudi patients with PM/DM-ILD managed at a tertiary centre. Methods: We conducted a retrospective cohort study (2006-2022) at a single tertiary hospital in Riyadh, Saudi Arabia. Adult patients (=18 years) with PM/DM by 2017 ACR/EULAR classification were re-adjudicated, and ILD was confirmed by high-resolution CT (HRCT) after blinded re-review by a thoracic radiologist. ILD patterns followed ATS/ERS categories (NSIP, UIP, OP, RB-ILD, unclassifiable). Severity was treated separately from pattern and operationalized as “mild” if HRCT parenchymal involvement was <20% or, when imaging was equivocal, if FVC =80% predicted. Demographics, clinical features, standard serologies, pulmonary function tests (PFTs), echocardiography, and treatments were abstracted using a standardized form with double-entry checks. Analyses were descriptive and exploratory; between-group comparisons were limited to subgroups with n=5 and adjusted for multiple testing (Holm). Results: Thirty-five patients met criteria (80% female; DM 60%, PM 40%). On HRCT rereview, NSIP was the most frequent pattern (37.1%, 13/35), followed by unclassifiable (14.3%, 5/35), UIP (5.7%, 2/35), RB-ILD (2.9%, 1/35), and OP (2.9%, 1/35). In parallel, severity was mild in 37.1% (13/35) across patterns. ILD timing relative to myositis was PM/DM-preceding in 48.6%, concomitant in 31.4%, and ILD-preceding in 20%. Exertional dyspnoea (74.3%) and non-productive cough (62.9%) were frequent; heliotrope rash and Gottron papules each occurred in 34.3%. ANA was positive in 82.9%; anti-Jo-1 in 34.3%. FVC (mean±SD) approximated 71% predicted overall; DLCO ~90% predicted where available. As pre-specified, no inferential tests were performed for subgroups with n<5 (UIP, RB-ILD, OP), and signals from small cells were treated descriptively only. Glucocorticoids were universally used; 77.1% were maintained at =7.5 mg/day. Mycophenolate mofetil (54.3%) and rituximab (48.6%) were the most common steroid-sparing agents; azathioprine (40%), methotrexate (34.3%), and IVIG (25.7%) were also used; antifibrotics were prescribed in 11.4%. Conclusion: In this Saudi tertiary-care cohort, NSIP predominated as the ILD pattern, while mild severity at presentation was common but distinct from pattern. The dataset underscores heterogeneity in serology and treatment and highlights the need for standardized radiologic severity grading, prospective PFT capture, and multicentre registries to refine prognosis and guide therapy in regional PM/DM-ILD.
Publication Details
Page(s) 136-145
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: S2, Year: 2025

Request the full text from PASTIC

Keywords
Interstitial lung disease, Myositis, Pulmonary Function Tests, Autoimmune Lung Disorders, High-Resolution Computed Tomography (HRCT)
References
Sun K.Y. .2020 .Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020.” Seminars in Arthritis and Rheumatism. , 11 : 175-191.
Dalakas M.C. .2015 .Inflammatory muscle diseases. ” New England Journal of Medicine, 10 : 1734-1747.
Schnabel A. . .Interstitial lung disease in polymyositis and dermatomyositis. Current Rheumatology Reports, 10(2005) : 99-105.
Findlay A.R. .2015 .An overview of polymyositis and dermatomyositis. ” Muscle and Nerve, 10 : 638-656.
Hara M. .2023 .Clinical risk factors for dysphagia and esophageal dysmotility in systemic sclerosis. ” Journal of Clinical Medicine, 10(10) : 3448.
Thoracic American .2002 .multidisciplinary consensus classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine, 10 : 277-304.
Marie I. .2002 .Interstitial lung disease in polymyositis and dermatomyositis. ” Arthritis and Rheumatism, 10 : 614-622.
Fathi M. .2003 .Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. ” Annals of the Rheumatic Diseases, 006122 : 297-301.
Bohan A.,J.B. Peter. A. .1975 .Polymyositis and dermatomyositis: first of two parts. ” New England Journal of Medicine, 10 : 344-347.
Bohan A.,J.B. Peter. A. .1975 .Polymyositis and dermatomyositis: second of two parts. ” New England Journal of Medicine, 10 : 403-407.
Hoppo T. . .Su1529 is idiopathic pulmonary fibrosis really idiopathic?: Patterns of reflux analyzed by bi-positional high-resolution manometry and hypopharyngeal multichannel intraluminal impedance. ” Gastroenterology, 5085(12) : 64096-7.
Njoroge M.W. .2021 .Changing lung function and associated health-related quality-of-life: A five-year cohort study of Malawian adults. ” EClinicalMedicine, 101166 : 101166.
Yang S.H. .2019 .Polymyositis and dermatomyositis - challenges in diagnosis and management. ” Journal of Translational Autoimmunity, 100018(2019) : 100018.
Reddy A. . .-following-dermatomyositis-a-case-linkingdepression-with-inflammation/.. ” Psychopharmacology Bulletin, 48(2018) : 22-28.
Košutova P.,Mikolka P. . .Aspiration syndromes and associated lung injury: incidence, pathophysiology and management. Physiological Research, 10(2021) : S567-S583.
Huang L. . .High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibodypositive dermatomyositis: Experience from a single center. ” Arthritis Research and Therapy, 10(2021) : 232.
Marie I. .2010 .Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Seminars in Arthritis and Rheumatism, 08(2011) : 48-60.
Mastaglia F.L. . .The changing spectrum of drug-induced myopathies. ” Acta Myologica, 10(2020) : 2532-288.
Schiopu E. . .Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: Effect of corticosteroids, methotrexate and azathioprine. Arthritis Research and Therapy, 10(2012) : R22.
Hallowell R.W.,Paik J.J. . .Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. ” Clinical and Experimental Rheumatology, 10(2022) : 373-383.
Marie I. . .Interstitial lung disease in polymyositis and dermatomyositis. ” Arthritis and Rheumatism, 10(2002) : 614-622.
Kim E.J. . .Rheumatoid arthritis-associated interstitial lung disease: The relevance of histopathologic and radiographic pattern. ” Chest, 10(2009) : 0444-1405.
Richter P. .2023 ."Interstitial lung disease in systemic lupus erythematosus and systemic sclerosis: how can we manage the challenge?". International Journal of Molecular Sciences, 10(11) : 9388.
Yunt Z.X.,Solomon J.J. .2014 ."Lung disease in rheumatoid arthritis." Rheumatic Disease Clinics of North America. , 12(2015) : 225-236.
Solomon J.J.,K.K. Brown J.J. . ."Rheumatoid arthritisassociated interstitial lung disease." Open Access Rheumatology. , 10(2012) : 21-31.
Demoruelle M.K. . ."When and where does inflammation begin in rheumatoid arthritis?" Current Opinion in Rheumatology. , 26(2014) : 64-71.
Hunter K.,Lyon M.G. . ."Evaluation and management of polymyositis.". Indian Journal of Dermatology, 10(2012) : 100479-5154.
Angum F. .2020 ."The prevalence of autoimmune disorders in women: a narrative review. " Cureus, 10(5) : .
Misra A.K. . ."Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies." BMC Pulmonary Medicine. , 10(2021) : 370.
Dalakas M.C.,Hohlfed R. .2003 ."Polymyositis and dermatomyositis." The Lancet. , 362 : 971-982.
Mende M. . ."Autoantibodies in myositis: how to achieve a comprehensive strategy for serological testing.". Mediterranean Journal of Rheumatology, 10(2019) : 155-161.
Raychaudhuri S.P.,Mitra A. . ."Polymyositis and dermatomyositis: disease spectrum and classification.". Indian Journal of Dermatology, 10(2012) : 100477-5154.
Park E.H. . ."Raynaud's phenomenon and anti-nuclear antibody are associated with pulmonary function decline in patients with dermatomyositis and polymyositis.". International Journal of Rheumatic Diseases, 10(2019) : 13456-185X.
Chen F. .2012 ."Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. " Rheumatology International, 10(12) : 3909-3915.
Moghadam-Kia S. . ."Antimelanoma differentiationassociated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. " Journal of Rheumatology, 10(2017) : 319-325.
De Lorenzo,R. Lorenzo .2018 ."Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. " Neurology, 10(23) : e2068-e2076.
Paik J.J. . ."Muscle disease in scleroderma." Current Opinion in Rheumatology. , 10(2018) : 576-580.
Lega J.C. .2014 ."The clinical phenotype associated with myositis-specific and associated autoantibodies: a metaanalysis revisiting the so-called antisynthetase syndrome. " Autoimmunity Reviews, 03(2014) : 883-891.
Lega J.C. . ."Interstitial lung disease associated with antiPM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?". Journal of Rheumatology, 10(2010) : 1000-1009.
Selva-O'Callaghan A. . ."Myositis-specific and myositisassociated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy." Arthritis and Rheumatism. , 10(2006) : 791-798.
Marie I. .2011 ."Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients." Arthritis and Rheumatism. , 10 : 3439-3447.
Ji S.Y. .2010 ."Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. " Chinese Medical Journal (English), 05 : 6999-522.
Koreeda Y. .2010 ."Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. " Internal Medicine, 10 : 361-369.
Fujisawa T. .2014 ."Prognostic factors for myositis-associated interstitial lung disease. " PLoS One, 0098824 : .
Douglas W.W. .2001 ."Polymyositis-dermatomyositisassociated interstitial lung disease." American Journal of Respiratory and Critical Care Medicine. , 10 : 1182-1185.
0

Citations

0

Downloads

45

Views